# Tissue Predictors of Abiraterone Benefit

> **NCT03176381** · — · COMPLETED · sponsor: **Tianjin Medical University Second Hospital** · enrollment: 110 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03176381
- **Lead sponsor:** Tianjin Medical University Second Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-05
- **Primary completion:** 2023-05-01
- **Final completion:** 2023-11-01
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2023-11-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03176381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03176381, "Tissue Predictors of Abiraterone Benefit". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03176381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*